首页> 外国专利> Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

机译:使用Adamts13治疗,改善和/或预防镰状细胞病,急性肺损伤和/或急性呼吸窘迫综合征的血管闭塞危机

摘要

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
机译:本公开内容提供了用于治疗,改善和/或预防患有镰状细胞疾病(SCD)的受试者的血管闭塞危机(VOC)的组合物和方法。 本公开还提供了用于治疗,改善和/或预防患有急性肺损伤(ALI)和/或急性呼吸窘迫综合征(ARDS)的受试者的受试者的肺损伤的组合物和方法。 本公开内容提供了一种脱胶苷和金属蛋白酶,其具有血压出型1型基序,构件-13(AdamTs13)或包含AdamTs13的组合物,用于治疗,改善和/或预防VOC,或用于治疗,改善和/或预防A. 受试者患有或有患有ALI和/或ARDS的风险。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号